Dehydroxyfluorafinil Stats & Data

Name/identity: This compound has been sold as “Modafiendz” and discussed as N‑methyl‑4,4'-difluoromodafinil; there is no peer‑reviewed human PK/toxicology, and marketed products may contain variable or mislabelled actives. User reports range from minimal effects to notable palpitations, highlighting batch inconsistency and possible adulteration or degradation. If the analogue shares modafinil’s liabilities, rare but serious cutaneous reactions (e.g., SJS/TEN/DRESS) are a concern; discontinue immediately at any rash or mucosal symptoms. Modafinil‑like CYP effects (3A4 induction; 2C19 inhibition) can meaningfully alter other drugs (e.g., methadone, diazepam) and potentially reduce effectiveness of some hormonal contraceptives—use extra protection while using and for weeks after, pending more data. Cardiovascular strain (tachycardia, BP elevation) and anxiety are reported; those with heart disease, arrhythmia history, or panic disorders should avoid or use only with medical oversight. Residual wakefulness can impair sleep architecture for 6–12 h after offset; avoid late dosing and plan sleep hygiene. Avoid combining with other stimulants or high caffeine to limit BP/HR spikes and jitteriness. Do not snort or inject: modafinil‑class compounds are poorly water soluble and not formulated for non‑oral routes; non‑oral use increases harm without added benefit. Due to frequent mislabeling in the unregulated market, consider drug checking where available; basic reagents are not definitive for this class, but MS‑based services can confirm composition. Until human data exist, treat all dosing guidance as provisional and titrate cautiously.